Novartis Buys Selexys On Favorable Phase II Data On SelG1
Zacks Investment Research | Nov 21, 2016 08:59PM ET
Swiss drug maker Novartis AG (NYSE:NVS) announced that it has acquired Selexys Pharmaceuticals Corporation, a privately held company specializing in the development of therapeutics for certain hematologic and inflammatory disorders, following the receipt of results from the phase II SUSTAIN study on SelG1 for the treatment of patients with sickle cell disease (SCD).
The study evaluated the use of SelG1, an anti-P-selectin antibody, in the reduction of vaso-occlusive pain crises in SCD patients. Results were presented at the plenary scientific session of the American Society of Hematology.
As per the terms of the agreement, the value of the transaction could reach $665 million, including upfront, acquisition and milestone payments.
We remind investors that Novartis had obtained the exclusive right to acquire Selexys and SelG1 in 2012.
The acquisition of Selexys represents an important step toward the continued development of SelG1, which will complement and expand Novartis’ hematology pipeline.
Considering the lack of FDA-approved drugs for SCD, there exists significant unmet for new treatment options.
Meanwhile, among other companies, GlycoMimetics, Inc. (NASDAQ:GLYC) is evaluating its pan-selectin antagonist, rivipansel, in a phase III study for the treatment of vaso-occlusive crisis in SCD, in collaboration with Pfizer Inc. (NYSE:PFE) . Rivipansel enjoys a Fast Track in the U.S., and orphan drug status in both the U.S. and the EU.
NOVARTIS AG-ADR Price
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.